<DOC>
	<DOC>NCT02177552</DOC>
	<brief_summary>The main purpose of this study is to determine the effects of treatment with carboplatin, docetaxel and capecitabine in patients with incurable cancer of the esophagus or stomach.</brief_summary>
	<brief_title>Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Key Patients with histologically verified, unresectable or metastatic, HER2negative, adenocarcinoma of the esophagus or stomach Men or women less than 80 years of age Performance status 0 or 1 Life expectancy &gt;12 weeks Adequate organfunction Written informed consent Key Prior chemotherapy for adenocarcinoma of the esophagus or stomach if the chemotherapyfree interval is less than 6 months Progression on firstline chemotherapy for unresectable or metastatic adenocarcinoma of the esophagus or stomach Chemotherapy with epirubicin, oxaliplatin, carboplatin, cisplatin or docetaxel less than 6 months before study entry Prior cumulative dose of &gt;300 mg/m2 of epirubicin Grade â‰¥ 2 sideeffects from previous chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Gastric cancer</keyword>
</DOC>